[Efficacy and Safety of Letrozole in Treatment of Male Children with Disorders of Sex Development]

Overview

Journal Zhejiang Da Xue Xue Bao Yi Xue Ban

Specialty General Medicine

Date 2020 Aug 8

PMID 32762157

Authors

Bingqing Yu

Min Nie

Xueyan Wu

Jiangfeng Mao

Xi Wang

Wanlu Ma

Wen Ji

Qibin Huang

Rui Zhang

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the efficacy and safety of aromatase inhibitor letrozole in treatment of male children with disorders of sex development (DSD).

Methods: Clinical data of 12 male DSD children with a mean age of 14.6±2.5 years admitted to Peking Union Medical College Hospital from January 2014 to January 2016 were retrospectively analyzed. The patients were treated with letrozole (1.25-2.5 mg, once a day) for 3 months or longer, and followed up for 0.5-2.5 years. Clinical manifestation and laboratory test findings were documented, and the efficacy and safety were evaluated.

Results: After half-year treatment, the blood luteinizing hormone (LH), follicle-stimulating hormone (FSH) and testosterone levels of patients increased (all < 0.05), and estrogen levels decreased from baseline ( < 0.05). After 1 year of treatment, the blood testosterone level was significantly higher ( < 0.05); the LH and FSH levels tended to increase and the estrogen level tended to decrease, but there was no significant statistical difference ( >0.05). Semen was routinely detected in 8 patients, and sperms were detected in semen of 3 patients with hypospadias. There were no significant changes in biochemical results after treatment, and no significant adverse event was observed during the treatment.

Conclusions: Letrozole can effectively increase testosterone levels in patients with disorders of sex development and promote spermatogenesis, it has no significant adverse effects in short-term administration.

References

Del Giudice F, Busetto G, De Berardinis E, Sperduti I, Ferro M, Maggi M . A systematic review and meta-analysis of clinical trials implementing aromatase inhibitors to treat male infertility. Asian J Androl. 2019; 22(4):360-367. PMC: 7406101. DOI: 10.4103/aja.aja_101_19. View

Wisniewski A, Batista R, Costa E, Finlayson C, Sircili M, Denes F . Management of 46,XY Differences/Disorders of Sex Development (DSD) Throughout Life. Endocr Rev. 2019; 40(6):1547-1572. DOI: 10.1210/er.2019-00049. View

Raman J, Schlegel P . Aromatase inhibitors for male infertility. J Urol. 2002; 167(2 Pt 1):624-9. DOI: 10.1016/S0022-5347(01)69099-2. View

Ma N, Geffner M . Gynecomastia in prepubertal and pubertal men. Curr Opin Pediatr. 2008; 20(4):465-70. DOI: 10.1097/MOP.0b013e328305e415. View

Wit J, Hero M, Nunez S . Aromatase inhibitors in pediatrics. Nat Rev Endocrinol. 2011; 8(3):135-47. DOI: 10.1038/nrendo.2011.161. View

Mehta A, Bolyakov A, Roosma J, Schlegel P, Paduch D . Successful testicular sperm retrieval in adolescents with Klinefelter syndrome treated with at least 1 year of topical testosterone and aromatase inhibitor. Fertil Steril. 2013; 100(4):970-4. DOI: 10.1016/j.fertnstert.2013.06.010. View

Tan R, Guay A, Hellstrom W . Clinical Use of Aromatase Inhibitors in Adult Males. Sex Med Rev. 2014; 2(2):79-90. DOI: 10.1002/smrj.23. View

Saltzstein D, Sieber P, Morris T, Gallo J . Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole. Prostate Cancer Prostatic Dis. 2005; 8(1):75-83. DOI: 10.1038/sj.pcan.4500782. View

Mitwally M, Casper R . Aromatase inhibitors for the treatment of infertility. Expert Opin Investig Drugs. 2003; 12(3):353-71. DOI: 10.1517/13543784.12.3.353. View

10.

Mehta A, Clearman T, Paduch D . Safety and efficacy of testosterone replacement therapy in adolescents with Klinefelter syndrome. J Urol. 2014; 191(5 Suppl):1527-31. DOI: 10.1016/j.juro.2013.09.015. View

11.

Schiff J, Palermo G, Veeck L, Goldstein M, Rosenwaks Z, Schlegel P . Success of testicular sperm extraction [corrected] and intracytoplasmic sperm injection in men with Klinefelter syndrome. J Clin Endocrinol Metab. 2005; 90(11):6263-7. DOI: 10.1210/jc.2004-2322. View

12.

Parada-Bustamante A, Rios R, Ebensperger M, Lardone M, Piottante A, Castro A . 46,XX/SRY-negative true hermaphrodite. Fertil Steril. 2010; 94(6):2330.e13-6. DOI: 10.1016/j.fertnstert.2010.03.066. View

13.

Loves S, de Jong J, van Sorge A, Telting D, Tack C, Hermus A . Somatic and psychological effects of low-dose aromatase inhibition in men with obesity-related hypogonadotropic hypotestosteronemia. Eur J Endocrinol. 2013; 169(5):705-14. DOI: 10.1530/EJE-13-0190. View

14.

Moon J, Ko C, Yang J, Lee J . Combined surgical and medical treatment in an adolescent with severe gynecomastia due to excessive estradiol secretion: a case report. BMC Pediatr. 2019; 19(1):515. PMC: 6931246. DOI: 10.1186/s12887-019-1887-7. View